The main purpose of the study is to learn more about how ALSP occurs and how the disease affects people over time. Study participants will not receive any investigational drugs as part of this study and will continue their standard of care treatment during the study.
Vigil Neuroscience is developing an investigational drug, iluzanebart (VGL101), for the treatment of people with ALSP. Our goal is that this natural history study will provide information that may help with the development of future treatments for ALSP, including iluzanebart. Enrollment in this study will not impact participants’ eligibility to enroll in future clinical studies that involve investigational drugs for the treatment of ALSP, such as iluzanebart.
Who can participate?
To participate in this study, individuals will need to meet the following main criteria*
- 18 years of age or older
- Documentation of a gene variant in the CSF1R gene
- Diagnosed with ALSP and have MRI findings consistent with ALSP
*There are additional inclusion and exclusion criteria for this study.
About the Illuminate Study
Study participation will last approximately 37 months and will include approximately 7 study visits to the study site.
During the study, blood samples will be collected along with MRI images, and performance and cognitive assessments and questionnaires.
Travel assistance and stipends for participation are available to participants and caregivers.
Eligible participants may have the opportunity to receive iluzanebart (VGL101) in a separate study after participating in this study. View the study listing and additional details including study sites and eligibility criteria on ClinicalTrials.gov.
Interested in learning more?
View the study listing and additional details including study sites and eligibility criteria
Explore resources to facilitate ongoing learning about the natural history study as well as support for individuals and families with ALSP.
If you're interested in participating in the study or would like more information, we'd love to hear from you.